Square Pharmaceuticals Ltd’s consolidated earnings per share (EPS) surged 16 per cent year-on-year in third quarter (Q3) for January-March, 2020.
The board of directors of the company in a meeting on Monday approved the third quarter (Q3) un-audited financial statements of the company for the period that ended on March 31, 2020.
The country’s leading Pharma Company’s consolidated net profit stood at Tk 3.62 billion in January-March, 2020 period, which was Tk 3.12 billion in the same quarter of the previous year, according to an official disclosure on Tuesday.
The company’s consolidated earnings per share (EPS) stood at Tk 4.28 for January-March 2020 as against Tk 3.69 for January-March 2019.
In nine months, the company’s consolidated net profit stood at Tk 10.50 billion for the period of July, 2019 to March 31, 2020 which was Tk 9.42 billion in the same period of year before.
The company’s consolidated EPS was Tk 12.44 for July 01, 2019 to March 31, 2020 as against Tk 11.15 for July 1, 2018 to March 31, 2019.
Its net operating cash flow per share was Tk 10.13 in third quarter ended on March 31, 2020 which was Tk 10.57 for the same period of the previous year.
The net asset value per share was Tk 88.19 as on March 31, 2020.
Each share of the company, which was listed on the Dhaka Stock Exchange in 1995, closed at Tk 172.50 on Monday.
Its share traded between Tk 156.50 and Tk 266.20 in the last one year.
The company disbursed 42 per cent cash and 7.0 per cent stock dividend for the year ended on June 30, 2019.
The company’s paid-up capital is Tk 8.44 billion and authorised capital is Tk 10 billion, while the total number of securities is 844.23 million.
The sponsor-directors own 34.57 per cent stake in company, while the institutional investors own 10.30 per cent, foreign investors 19.48 per cent and the general public 35.65 per cent as on February 29, 2020, the DSE data showed.